had improvement in residual limb and phantom limb pain post-operatively. The objective of this randomized clinical trial is to compare TMR as a treatment option for amputeerelated pain to the current standard of care for end-neuromas, which entails neurectomy and muscle-burying.
RESULTS:
With an average follow up of almost 18 months, patients undergoing TMR had a significant reduction in both phantom limb and residual limb scores compared to preoperative values. Specifically, average phantom pain levels decreased from 5.7 (0-10 scale) pre-operatively to 1.8 postoperatively, and average residual limb pain decreased from 6.7 pre-operatively to 3.4 post-operatively (all p<0.05). Standard treatment failed to yield any significant improvement in phantom pain (3.9 pre-operative vs 4.3 post-operative) with only minimal improvement in residual limb pain values (6.9 pre-operatively versus 5.7 post-operatively, p>0.05). The percentage of patients who had no phantom pain (NRS score of zero) increased from 16.7% to 50% in the TMR cohort. There were few individuals free from residual limb pain before or after surgery in either intervention arm. The percentage of individuals dealing with mild pain (NRS score 1-3) increased from 0% to 66.7% in the TMR cohort. Conversely, the number of individuals suffering from severe phantom limb or severe residual limb pain (NRS 7-10) increased in the standard treatment arm post-operatively. The trial was ultimately stopped in light of the noted failures and lack of overall improvement seen in the standard arm.
CONCLUSION:
Results from this randomized clinical trial reveal that Targeted Muscle Reinnervation provides profound long-term improvement in phantom limb pain and residual limb pain in major limb amputees. TMR should be the treatment of choice for chronic pain in amputees as the results from standard therapy were disappointing for patient outcomes. The main goals for reconstruction of these areas are to provide color and texture match and to minimize donor-area morbidity. 2 As the glabellar region has a rich vascular network, it is highly suitable for perforator flaps. Therefore, we designed a perforator propeller flap based on the central artery.
Central Artery Perforator Propeller

PATIENTS AND METHODS:
This prospective clinical study included 34 patients (14 females and 20 males) who had undergone surgery between January 2014 and March 2017. The median age of the patients was 60 (range: 19-88 years). All patients were followed up for at least 6 months.
RESULTS:
The pathological diagnoses were basal cell carcinoma(n=19) and squamous cell carcinoma (n=12). Two of the defects were after trauma. The median followup was nine months (ranged:6-32months). The size of the defects ranged from 2 x 2 to 4 x 5 cm, and that of the flaps ranged from 2 x 3.5 to 5x10 cm. We did not observe any major complications requiring surgery, such as total flap loss, hematoma, or dog-ear deformity. Venous congestion was observed in five patients, two of whom showed partial flap loss. Partial flap loss in largest flap (5 x 10cm) due to lack of arterial inflow into the tip of the flap. Although all of them healed without any intervention, only one required partial suture removal. None of the patients underwent secondary surgery for aesthetic reasons.
DISCUSSION:
The forehead flap is a safe and reliable option for the reconstruction of any skin component of the nose and medial canthal region. The disadvantages of the conventional forehead flap are as follows: need for at least one more surgery for pedicle separation, eyebrow deformity, vertical forehead scar, hair transfer to the reconstructed area, bulged-out appearance of the flap in comparison with the recipient area, and frequent occurrence of hypesthesia over the superior forehead (as the supratrochlear nerve is included in the flap).
3, 4 None of our patients experienced hypesthesia on the forehead and
